The value of vesicant f-fluorodeoxyglucose positron emission tomography (f-fdg pet) in gastric malignancies

Nuclear Medicine Communications

Volumn 25, Issue 8, 2004, Pages 825-831

  Tian, Jiahe ^a   Chen, Lin ^a   Wei, Bo ^a   Shao, Mingzhe ^a   Ding, Yong ^a   Yin, Dayi ^a   Yao, Shulin ^a  

^a Surgery   (United States)

Author keywords

Neoplasm staging; Positron emission tomography; Stomach neoplasms; Vesicant

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; IRRITANT AGENT; RADIOPHARMACEUTICAL AGENT; CARBON DIOXIDE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STOMACH TUMOR; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DRUG UPTAKE; GASTROSCOPY; HUMAN TISSUE; LABORATORY DIAGNOSIS; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; STOMACH BIOPSY; STOMACH CARCINOMA; THREE DIMENSIONAL IMAGING; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IRRITANTS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 4143072424     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000135042.54461.f6     Document Type: Article

References (10)

1. Lerut T, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000; 232:743-752.
2. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002; 29:525-529.
3. Montravers F, Kerrou K, Grahek D, Zerbib E, Mabille L, Younsi N, et al. Value of [18F]-fluorodeoxyglucose (FDG) positron emission tomography in digestive cancerology. Presse Med 2002; 31:1560-1568.
4. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003; 58:215-221.
5. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224:748-756.
6. McAteer D, Wallis F, Couper G, Norton M, Welch A, Bruce D, et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999; 72:525-529.
7. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003; 30:288-295.
8. Bender H, Palmedo H, Biersack HJ, Valk PE. Atlas of Clinical PET in Oncology: PET Versus CT and MRI. New York: Springer Verlag; 2000, pp. 11-14.
9. Ding Y, Tian JH, Wei B, Zhang SW, Shao MZ, Chen L, et al. The diagnosis of gastric cancer with 18F-FDG PET and its influencing factors. Chin J Med Imaging 2003; 11:320-323 (in Chinese).
10. Hoffmann M, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10:1185-1189.